Literature DB >> 25068992

Bufotalin-induced apoptosis in osteoblastoma cells is associated with endoplasmic reticulum stress activation.

Yun-Rong Zhu1, Yong Xu2, Jian-Feng Fang1, Feng Zhou1, Xiong-Wei Deng1, Yun-Qing Zhang3.   

Abstract

The search for novel and more efficient chemo-agents against malignant osteoblastoma is important. In this study, we examined the potential anti-osteoblastoma function of bufotalin, and studied the underlying mechanisms. Our results showed that bufotalin induced osteoblastoma cell death and apoptosis in dose- and time-dependent manners. Further, bufotalin induced endoplasmic reticulum (ER) stress activation in osteoblastoma cells, the latter was detected by the induction of C/EBP homologous protein (CHOP), phosphorylation of inositol-requiring enzyme 1 (IRE1) and PKR-like endoplasmic reticulum kinase (PERK), as well as caspase-12 activation. Conversely, the ER stress inhibitor salubrinal, the caspase-12 inhibitor z-ATAD-fmk as well as CHOP depletion by shRNA significantly inhibited bufotalin-induced osteoblastoma cell death and apoptosis. Finally, by using a mice xenograft model, we demonstrated that bufotalin inhibited U2OS osteoblastoma cell growth in vivo. In summary, our results suggest that ER stress contributes to bufotalin-induced apoptosis in osteoblastoma cells. Bufotalin might be investigated as a novel anti-osteoblastoma agent.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Apoptosis and signaling; Bufotalin; ER stress; Osteoblastoma

Mesh:

Substances:

Year:  2014        PMID: 25068992     DOI: 10.1016/j.bbrc.2014.07.077

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  14 in total

1.  Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against osteosarcoma.

Authors:  Yun-Rong Zhu; Han Min; Jian-Feng Fang; Feng Zhou; Xiong-Wei Deng; Yun-Qing Zhang
Journal:  Cancer Biol Ther       Date:  2015-04-14       Impact factor: 4.742

2.  The Antipancreatic Cancer Activity of OSI-027, a Potent and Selective Inhibitor of mTORC1 and mTORC2.

Authors:  Bo Chen; Ming Xu; Hui Zhang; Ming-zheng Xu; Xu-jing Wang; Qing-he Tang; Jian-ying Tang
Journal:  DNA Cell Biol       Date:  2015-08-18       Impact factor: 3.311

3.  Autophagy inhibition sensitizes WYE-354-induced anti-colon cancer activity in vitro and in vivo.

Authors:  Lijun Wang; Yun-Rong Zhu; Shaowei Wang; Song Zhao
Journal:  Tumour Biol       Date:  2016-03-28

4.  Ophiopogonin D maintains Ca2+ homeostasis in rat cardiomyocytes in vitro by upregulating CYP2J3/EETs and suppressing ER stress.

Authors:  Wen-ting You; Tao Zhou; Zeng-chun Ma; Qian-de Liang; Cheng-rong Xiao; Xiang-lin Tang; Hong-ling Tan; Bo-li Zhang; Yu-guang Wang; Yue Gao
Journal:  Acta Pharmacol Sin       Date:  2016-02-01       Impact factor: 6.150

5.  Dual targeting of mTORC1 and mTORC2 by INK-128 potently inhibits human prostate cancer cell growth in vitro and in vivo.

Authors:  Shang-Jun Jiang; Shuo Wang
Journal:  Tumour Biol       Date:  2015-05-21

6.  Small Molecular TRAIL Inducer ONC201 Induces Death in Lung Cancer Cells: A Preclinical Study.

Authors:  Yuan Feng; Jihong Zhou; Zhanhua Li; Ying Jiang; Ying Zhou
Journal:  PLoS One       Date:  2016-09-14       Impact factor: 3.240

7.  microRNA-135b expression silences Ppm1e to provoke AMPK activation and inhibit osteoblastoma cell proliferation.

Authors:  Zheng-Wei Li; Yun-Rong Zhu; Xiao-Zhong Zhou; Bao-Biao Zhuo; Xiao-Dong Wang
Journal:  Oncotarget       Date:  2017-04-18

8.  Preclinical study of cinobufagin as a promising anti-colorectal cancer agent.

Authors:  Xing-Sheng Lu; Yin-Biao Qiao; Ya Li; Bo Yang; Min-Bin Chen; Chun-Gen Xing
Journal:  Oncotarget       Date:  2017-01-03

9.  Identification of DNA-PKcs as a primary resistance factor of salinomycin in osteosarcoma cells.

Authors:  Yun-Fang Zhen; Song-Tao Li; Yun-Rong Zhu; Xiao-Dong Wang; Xiao-Zhong Zhou; Lun-Qing Zhu
Journal:  Oncotarget       Date:  2016-11-29

10.  The anti-cancer activity of the mTORC1/2 dual inhibitor XL388 in preclinical osteosarcoma models.

Authors:  Yun-Rong Zhu; Xiao-Zhong Zhou; Lun-Qing Zhu; Chen Yao; Jian-Feng Fang; Feng Zhou; Xiong-Wei Deng; Yun-Qing Zhang
Journal:  Oncotarget       Date:  2016-08-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.